The use of systemic anticancer chemotherapy is intrinsically limited by its toxicity. Whether
dealing with small molecules or biopharmaceuticals, after systemic administration, small …

Serum albumin physically interacts with fatty acids, small molecules, metal ions, and several
other proteins. Binding with a plethora of bioactive substances makes it a critical transport …

Brain cancer, especially the most common type of glioblastoma, is highly invasive and
known as one of the most devastating and deadly neoplasms. Despite surgical and medical …

Two decades ago successful transfection of antigen presenting cells (APC) in vivo was
demonstrated which resulted in the induction of primary adaptive immune responses. Due to …

Serum albumin, a natural ligand carrier that is highly concentrated and long-circulating in
the blood, has shown remarkable promise as a carrier for anti-cancer agents. Albumin is …

The present narrative review on albumin dialysis provides evidence-based and expert
opinion guidelines for clinicians caring for adult patients with different types of liver failure …

Proteins and enzymes are versatile biomaterials for a wide range of medical applications
due to their high specificity for receptors and substrates, high degradability, low toxicity, and …

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic
levels, however, challenges such as rapid renal clearance, degradation or non-specific …

Platinum drugs have been a mainstay of cancer chemotherapy since the introduction of
cisplatin in the 1970s. Since then, carboplatin and oxaliplatin have been approved world …

Nutrient transporters have been explored for biomimetic delivery targeting the brain. The
albumin-binding proteins (eg, SPARC and gp60) are overexpressed in many tumors for …